Effects of Clazakizumab on Anemia and Iron Metabolism in Patients with Kidney Failure

Collaborators, Affiliations

on behalf of the POSIBIL ESKD Investigators:
Glenn M Chertow, Myles Wolf, David Charytan, G Michael Felker, Bengt Fellstrom, C Michael Gibson, Meg Jardine, Adeera Levin, Yuliya Lokhnygina, Kenneth W Mahaffey, Roxana Mehran, Brendon L Neuen, Peter Stenvinkel, Angela Yee Moon Wang, Carmine Zoccali, Paul Ridker, David C Wheeler, Shaun Goodman, Rathika Krishnasamy, Michel Jadoul, David Collister, Zuo Li, My Hanna Sofia Svensson, Ziad Massy, Kai-Uwe Eckardt, Pantelis Sarafidis, Andras Tisler, Yoram Yagil, Norio Hanafusa, Sunita Bavanandan, Seow Yeing Yee, Magdalena Madero, Andrzej Wiecek, Ana Carina Costa Ferreira, Ionut Nistor, Hyeong-Cheon Park, Maria Jose Soler, Mai-Szu Wu, Arkom Nongnuch, Sinee Disthabanchong, Mustafa Arici, Mark Lambie, Simon Davies, Anna Marie Chang

¹ The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
² Department of Renal Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia.
³ Division of Nephrology, Duke University, Durham, North Carolina.
⁴ CSL Behring LLC, King of Prussia, Pennsylvania.
⁵ Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin Berlin, Berlin, Germany.
⁶ Division of Cardiology, Duke University and Duke Clinical Research Institute, Durham, North Carolina.
⁷ Department of Medicine, Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, California.
⁸ Joan and Sandford I Weill Department of Medicine, Weill Cornell Medicine, Cornell University, New York, New York.

Brendon L Neuen et al. J Am Soc Nephrol. 2025.

. 2025 May 1;36(5):923-925.

doi: 10.1681/ASN.0000000654. Epub 2025 Feb 5.

on behalf of the POSIBIL ESKD Investigators:
Glenn M Chertow, Myles Wolf, David Charytan, G Michael Felker, Bengt Fellstrom, C Michael Gibson, Meg Jardine, Adeera Levin, Yuliya Lokhnygina, Kenneth W Mahaffey, Roxana Mehran, Brendon L Neuen, Peter Stenvinkel, Angela Yee Moon Wang, Carmine Zoccali, Paul Ridker, David C Wheeler, Shaun Goodman, Rathika Krishnasamy, Michel Jadoul, David Collister, Zuo Li, My Hanna Sofia Svensson, Ziad Massy, Kai-Uwe Eckardt, Pantelis Sarafidis, Andras Tisler, Yoram Yagil, Norio Hanafusa, Sunita Bavanandan, Seow Yeing Yee, Magdalena Madero, Andrzej Wiecek, Ana Carina Costa Ferreira, Ionut Nistor, Hyeong-Cheon Park, Maria Jose Soler, Mai-Szu Wu, Arkom Nongnuch, Sinee Disthabanchong, Mustafa Arici, Mark Lambie, Simon Davies, Anna Marie Chang

¹ The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
² Department of Renal Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia.
³ Division of Nephrology, Duke University, Durham, North Carolina.
⁴ CSL Behring LLC, King of Prussia, Pennsylvania.
⁵ Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin Berlin, Berlin, Germany.
⁶ Division of Cardiology, Duke University and Duke Clinical Research Institute, Durham, North Carolina.
⁷ Department of Medicine, Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, California.
⁸ Joan and Sandford I Weill Department of Medicine, Weill Cornell Medicine, Cornell University, New York, New York.

No abstract available

Keywords: anemia; chronic hemodialysis; chronic inflammation; hemodialysis.

Conflict of interest statement

Disclosure forms, as provided by each author, are available with the online version of the article at http://links.lww.com/JSN/F67.

1. Chertow GM Chang AM Felker GM, et al. . IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial. Nat Med. 2024;30(8):2328–2336. doi:10.1038/s41591-024-03043-1 - DOI - PMC - PubMed
1. Pergola PE Devalaraja M Fishbane S, et al. . Ziltivekimab for treatment of anemia of inflammation in patients on hemodialysis: results from a phase 1/2 multicenter, randomized, double-blind, placebo-controlled trial. J Am Soc Nephrol. 2021;32(1):211–222. doi:10.1681/ASN.2020050595 - DOI - PMC - PubMed
1. Pergola PE Davidson M Jensen C, et al. . Effect of ziltivekimab on determinants of hemoglobin in patients with CKD stage 3–5: an analysis of a randomized trial (RESCUE). J Am Soc Nephrol. 2024;35(1):74–84. doi:10.1681/ASN.0000000000000245 - DOI - PMC - PubMed